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Abstract 
Purpose: To evaluate the effect of tangeretin on ovalbumin (OVA)-induced allergic respiratory asthma 
in Swiss albino mice.  
Methods: Mice were injected intraperitoneally with 50 μg OVA dissolved in water and 1 mg of 
aluminium hydroxide (alum) on the first day, and on day 12. On days 22, 26 and 30, the mice were 
exposed to 1 % OVA for 30 min. Mice in the asthma control group received saline via the same route. 
Tangeretin (50 or 100 mg/kg body weight) was given orally from day 1 to day 30. On the day of 
sensitization and challenge, tangeretin (50 or 100 mg/kg body weight) was injected 30 min prior to the 
treatment. Bronchial function, degree of inflammation, broncho-alveolar lavage fluid (BALF), levels of  
IL-4, IL-5, IL-13 and IFN-γ in BALF, serum total IgE, OVA-specific IgE, IgG1 and IgG2a, as well as 
histopathology of lungs were determined.  
Results: Tangeretin administration led to significant reduction in airway sensitivity, and significant 
decreases in leukocyte, macrophage, and eosinophil counts (p < 0.05). It also brought about significant 
decreases in the levels of the pro-inflammatory cytokines (IL-4, IL-5 and IL-13) in both BALF and serum 
(p < 0.05). In addition, tangeretin reversed the OVA-induced histopathological anomalies in the lungs.  
Conclusion: These results demonstrate that tangeritin exerts protective effects against OVA-induced 
allergic respiratory asthma in Swiss albino mice, and that the drug can potentially be developed for the 
management of allergic asthma. 
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Asthma is a severe, long-lasting inflammatory 
ailment characterised by reversible respiratory 
airway congestion. Presently, it affects about 300 
million persons globally, and its incidence 
increases at the rate of 50 % per decade [1]. 
Respiratory inflammation results in intermittent 
wheezing, shortness of breath and chest 
congestion, particularly during the evening 
period, and in the early hours of the day. These 
events are normally connected with respiratory 
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blockage. Allergic respiratory inflammation is 
thought to be aggravated by changes in the 
levels of cytokines [2]. Presently, the precise 
pathway for the development of asthma is 
uncertain. Despite the use of extant drugs for 
asthma (mostly β2 receptor antagonists), 
exacerbations of asthmatic symptoms still occur, 
probably because these agents do not cause 
alterations in the causative pathological 
pathways [2].  
 
Several animal models for screening anti-
asthmatic effects of new pharmacological 
interventions have been developed. In the 
present study, allergy-based animal model was 
used. 
 
Tangeretin is one of the important 
polymethoxylated flavones abundantly available 
in citrus fruits. Studies have shown that 
tangeretin possesses anti-cancer, antioxidant 
and anti-inflammatory properties [3-5]. Apart from 
its antioxidant property, tangeretin has been 
shown to reduce the development of hepatic 
cancer in vivo as well as in vitro [6].  
 
In the present study which was based on the 
extensive beneficial properties of tangeretin, the 
anti-inflammatory and immunomodulatory 
activities of tangeretin were investigated in a 
mouse model of allergic asthma. The chemical 











In this study, 6-8 week-old male BALB/c mice 
were used. The experimental animals were 
housed in cages in a well-ventilated room at with 
average temperature of 23 ± 2 °C, and 61 ± 4 % 
moisture. The mice were given normal laboratory 
feed and water ad libitum, and were assigned to 
four different groups. Group I mice were injected 
with saline (intra peritoneal (i.p.) route) and 
served as normal control group, and group 2 
(OVA) group was treated with OVA (i.p.), and 
served as bronchial airway asthma control group. 
Mice in group 3 were treated with OVA (i.p.) and 
50 mg/kg tangeretin, while mice in group 4 
received OVA (i.p.) and 100 mg/kg tangeretin.  
The study was approved by the Institutional 
Ethical Committee (approval no. 2017/2033). It 
was carried out in accordance with Good Clinical 
Practice and the Declaration of Helsinki 
Guidelines and all applicable regulatory 
requirements [7]. A schematic diagram of the 
study is shown in Figure 2. 
 
Chemicals and reagents 
 
In this study, the following chemicals and 
reagents were commercially obtained: OVA and 
100 % pure, endotoxin-free tangeretin (Simcere 
Doyea Pharmaceutical Co., China); bovine 
serum albumin (BSA, Atlanta Biologicals, 
Lawrenceville, GA, USA)); pancuronium bromide 
(Xi'an Miracle Biotechnology Co., Ltd.); anti-
dinitrophenol (anti-DNP) and IgE mab (Atlanta 
Biologicals, Lawrenceville, USA); peroxidase- 
labeled anti-mouse IgE and goat IgG polyclonal 
antibody (Atlanta Biologicals (Lawrenceville, 
 
 
Figure 2: Schematic diagram of the study. Animals were actively sensitized by intraperitoneal injections of 50 μg 
OVA with 1 mg alum on days 1 and 12. On 22nd, 26th and 30th days, they were exposed to OVA (1 % (w/v) in 
sterile physiological saline) for 30 min, each day. The negative control group mice were exposed to saline in a 
similar manner. Twenty-four hours after the final antigen challenge (on 31st day), bronchial responsiveness to Ach 
was measured; BALF was collected, and lung sections were removed for histopathology. (Tangeritin was 
administered orally from day 1 to day 30. On the day of sensitization and challenge, tangeritin was given 30 min 
before the treatment) 
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USA); rat anti-mouse IgE mab (Santa Cruz, 
USA); goat anti-mouse IgG1 polyclonal antibody 
(Santa Cruz, USA); rat anti-mouse IgG2a mab 
(Invitrogen, Carlsbad, CA, USA); and 
peroxidase-conjugated streptavidin (Santa Cruz, 
USA). 
 
Sensitization and challenge 
 
The experimentations in this study were 
performed according to the procedures described 
by Balaha et al [8]. The experimental animals 
were sensitized by administering 50 μg OVA 
(intraperitoneally) and 1 mg of alum on day 1 and 
day 12. Furthermore, on days 22, 24 and 30, the 
animals were injected with 1 % w/v solution of 
OVA in sterilized saline, 3 times each day. Mice 
in the normal control group were administered 
saline in the same manner. On day 31, after the 
last antigenic injection, the sensitivity of the 
respiratory mucous muscle to acetylcholine (Ach) 
was measured. Bronchial-alveolar lavage fluid 
(BALF) and lungs were collected for 
histopathological studies. Tangeretin was 
injected for 30 days (from day 1 to day 30). On 
the sensitization day, tangeretin was 
administered 30min prior to treatment (Figure 2). 
 
Measurement of airway function 
 
Bronchoconstriction was measured in 
accordance with the procedure of Balaha et al 
[8]. The experimental animals were anesthesized 
by intraperitoneal administration of sodium 
pentobarbitone (60 mg/kg), and Ach was 
administered through jugular vein cannulation. 
Furthermore, intravenous pancronium bromide 
(0.1 mg/kg) was injected to suppress inhalation, 
and the mice were allowed ventilation from 
oxygen-filled air at 120 beats/min, with beat size 
of 0.3 ml/mouse. Respiratory constriction was 
tested by employing respiratory spasm 
transducer coupled to tracheal cannula. To 
determine respiratory tract sensitivity towards 
Ach, anomalies in bronchial excess volume were 
determined by employing ascending doses of 
Ach. Excess respiratory airflow exhibited by Ach 
was demonstrated as percentage of the maximal 
excess flow volume (100 %) attained by 
fastening the respiratory tract cannula. The area 
under curve was measured from a dose–
response curve of Ach (range: 30.25 to 2,000 
μg/kg). Each dose was transformed 
logarithmically, and the area under curve was 
measured and depicted as arbitrary units. 
 
Tests on BALF  
 
The accumulation of inflammation mediators in 
BALF was tested to determine respiratory tract 
inflammation. The experiments were performed 
according to the method of Balaha et al. [8]. 
Twenty-four hours after the terminal inhalational 
dose of the antigenic agent, the experimental 
animals were sacrificed under intraperitoneal 
sodium pentobarbitone (100 mg/kg) anaesthesia. 
The left bronchial tissue was knotted for 
histopathological studies, and the right airway 
tract was splashed four times with 0.5 ml of 
phosphate buffered saline (PBS). The BALF from 
each mouse was collected in a plastic tube, 
chilled in icepack, and centrifuged at 150 × g for 
10 min at 4 °C. The resultant cell capsules were 
suspended in an equivalent volume of buffer (1 
mL). One part of the cell suspension was then 
suspended in Türk solution, and the nucleated 
cells were measured in a Bürker cubicle. A 
differentiating count was done on a cover slip 
smear made using a cyto-centrifuge, and then 
marked with Diff-Quick solvent. According to 
standard diagnostic selection, 300 cells were 
measured at an amplification of × 500. 
 
Determination of cytokine concentrations 
in BALF 
 
The cytokine content of BALF suspension was 
analysed utilizing Biovision enzyme-linked 
immunosorbent assay (ELISA) kits for 
interleukin-4 (IL-4), interferon-γ, interleukin-5 (IL-
5) and interleukin-13 (IL-13).  
 
Assay of serum immunoglobulin (Ig) 
concentrations  
 
After administering the terminal dose on day 30, 
sera samples were subjected to cryo-
centrifugation at −30 oC, and the resultant 
supernatants were used for further analysis. 
Total IgE, ovalbumin-specific IgE, ovalbumin-
specific IgG1 and ovalbumin-specific IgG2a in 
the serum were determined by ELISA in line with 
the method of Balaha et al [8]. Total serum IgE 
was calculated by coating flat-bottomed 
microtiter plates with rat anti-mouse IgE mab (5 
μg/mL). After blocking with 1 % Block-Ace, the 
reference and serum dilutions were left to stand 
for one hour and then treated with peroxidase-
labeled anti-mouse immunoglobulin E goat IgG 
polyclonal antibody. Diluted anti-DNP IgE mab 
was used as a reference. 
 
Serum ovalbumin-specific IgE was determined 
by coating the microtiter plates with rat anti-
mouse IgE antibody mab (5 μg/mL). Blocking 
was done with 1 % BSA, and serum dilutions 
were left to stand for about one-hour. Serum 
ovalbumin-specific IgG1 was assayed by coating 
the microtiter plates with goat anti-mouse IgG1 
polyclonal antibody (2 μg/mL). On coating with 1 
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% BSA, serum dilutions were kept for 1 h 
followed by treatment with biotinylated-ovalbumin 
and peroxidase-conjugated streptavidin. Serum 
ovalbumin-specific immunoglobulin G2a was 
determined by layering the microtiter plates with 
ovalbumin solvent (20 μg/mL). Similarly, serum 
dilutions were kept for 1 h followed by treatment 
with peroxidase-conjugated monoclonal rat anti-
mouse IgG2a antibody. Sequentially diluted 
monoclonal anti-OVA IgE, IgG1, and IgG2a were 
employed as reference standards. Absorbance 
was measured in a programmed ELISA detector 
at 492 nm. The limit of detection was 1 ng/mL for 
aggregate IgE, anti-ovalbumin IgE, and anti-
ovalbumin IgG1. For anti-ovalbumin IgG2a, the 




The left-side lung tissue sections of the animals 
were separated and fixed in newly-prepared 10 
% formalin for about 24 h. The fixed tissues were 
thereafter embedded in paraffin, and 5μm 
sections were cut and stained with Hematoxylin 





Data are expressed as mean ± SEM, and were 
analysed by SPSS Statistics. Correlations were 
determined by one-way analysis of variance 
(ANOVA), followed by Tukey's test where 
appropriate. P ≤ 0.05 was considered as 




Effect of tangeretin on antigen-induced 
airway hyper-responsiveness 
 
Inhalation of OVA caused airway hyper-
responsiveness to Ach exposure, when 
compared to normal saline-treated animals. 
Exposure to tangeretin during OVA inhalation 
substantially prevented the OVA-provoked 
airway hyper-responsiveness in a dose-
dependent fashion (Figure 3 A and B). 
 
Effect of tangeretin on antigen-provoked 
airway eosinophilic inflammation 
 
The inhalation of OVA significantly increased 
total amount of inflammation mediatory cells, 
including macrophages and eosinophils in BALF. 
The accrual of inflammation mediatory cells in 
BALF was significantly prevented by 100 mg/kg 
tangeretin (Figure 3 C – F). Compared with 
inflammatory infiltrates, the concentrations of 
cytokines (Th2) such as Il-4, IL-5 and IL-13 in 
BALF were substantially increased, while BALF 
levels of Th1 cytokines and interferon-γ were 
significantly reduced (Figure 4). In line with its 
effect on respiratory eosinophilic inflammation, 
tangeretin administration was associated with 
reduction in proinflammatory cytokines and Th2 
cytokines, and increased Th1 cytokine 
concentrations in BALF (Figure 3). 
 
 
Figure 3: Effect of tangeritin on increased airway responsiveness to Ach and inflammatory infiltrates in BALF in 
OVA-induced bronchial asthma of BALB/c mice 
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Figure 4: Effect of tangeritin on increased cytokine levels in BALF in OVA-induced bronchial asthma of BALB/c 
mice 24-h after the final antigen challenge. Values represent mean ± SEM for six animals in each group. A= IL-4, 
B = IL-13, C = IFN-γ, D = IL-5. Saline = saline exposed group; OVA = non-treated bronchial asthma group; TNG 
50 mg/kg = bronchial asthma group treated with 50mg/kg tangeritin. #P < 0.05, ##p <0.01, ###p < .001 (vs. saline 
group); *p < 0.05, **p < 0.01, ***p <. 001 (vs. OVA group) 
 
Effect of tangeretin on serum immune-
glbulins 
 
Parenteral and local ovalbumin insult markedly 
raised the levels of serum total IgE, ovalbumin-
specific IgE, IgG1 and IgG2a. Pre-treatment with 
tangeretin significantly reversed the increases in 
concentrations of total IgE, ovalbumin-specific 
IgE and IgG1 in a dose-dependent fashion. On 
the other hand, tangeretin significantly increased 
the levels of ovalbumin-specific IgG2a at a dose 
of 100 mg/kg (Figure 5). 
 
Effect of tangeretin on histopathological 
abnormalities 
 
Figure 6 shows representative photomicrographs 
of lung tissue sections of the experimental animal 
groups (H&E). Ovalbumin (OVA) injection 
resulted in perivascular and peribronchial cellular 
infiltration, raised condensation of respiratory 
tracheal muscle, epithelial hyperplasia, and 
flaked epithelial lining. However, injection of 
tangeretin at a dose of 100 mg/kg substantially 
ameliorated the histopathological anomalies 




In this study, the immunomodulatory and anti-
inflammatory activities of tangeretin were 
determined in a mouse model of bronchial 
asthma in relation to bronchial function, antigen-
prompted, inflammation-mediated fluid secretion 
in the bronchial airways, local cytokine (Th1/Th2) 
secretion, serum immunoglobulin contents, and 
lung histopathology. Several animal models have 
been developed for studying new 
pharmacological interventions for allergic 
asthma. In the present study, experimental mice 
model was chosen. This model can simulate all 
the characteristic traits of bronchial inflammation 
in humans [9].  
 
In the present investigation, tangeretin 
administration in mice challenged with OVA 
substantially improved airway hyper-
responsiveness, decreased total counts of 
eosinophils, macrophages and leukocytes, and 
reduced the concentrations of proinflammatory 
cytokines in BALF. Serum concentrations of 
OVA-specific IgE, total IgE and IgG1 were also 
significantly reduced by tangeretin. 
 
Generally, Th-2 type 2 cytokines (Il-4, Il-5 and Il-
13) act as crucial factors in the precipitation of 
bronchial asthma in humans [10]. Among these 
cytokines, IL-4 stimulates the separation and 
propagation of Th2-type T-cells, and promotes 
the secretion of IgG1 and IgE by B-cells. Stalling 
of IL-4 by monoclonal antibodies (MABs) reduces 
IgE concentration and bronchial eosinophilia in 
hypersensitive mouse [11]. Interleukin-5 can 
function as a vital contributor in the segregation, 
maturation and survival of eosinophils, which 
accounts for its rise in bronchial constriction. 
Previous studies have demonstrated that 
eosinophilia-induced inflammation would not 
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Figure 5: Effect of tangeritin on increased serum immunoglobulin levels in OVA-induced bronchial asthma of 
BALB/c mice after the final allergen challenge. Values represent mean ± S.E.M. for six animals in each group. A 
= Total IgE, B = OVA-specific IgE, C = Ova-specific IgG1, D = OVA-specific IgG2a, Saline = saline-exposed 
group; OVA = non-treated bronchial asthma group; TNG 50mg/kg = bronchial asthma group treated with 50mg/kg 





Figure 6: Effect of TNG on histopathological 
alterations of lung tissues in OVA-induced bronchial 
asthma in BALB/c mice. A: Saline exposed group, 
B:Non-treated bronchial asthma group, C: Bronchial 
asthma group treated with TNG 50 mg/kg, D: 
Bronchial asthma group treated with TNG 100 mg/kg 
(H&E staining, × 200) 
 
develop without the activity of interleukin-5 or 
without its function in the trachea of OVA-treated 
animals [12].  
 
Interleukin-13 is implicated in airway hyper-
responsiveness. It induces IgE isotype switch-
over in B-cells and mucus secretion in the 
bronchial airways. It has been shown that IL-13 
knockout mouse failed to develop airway hyper-
responsiveness from allergen exposure even 
after developing severe bronchial inflammatory 
reaction [13]. In contrast to the Th2 cytokines, 
inteferon-γ secreted by Th1 cells can increase 
secretion of IgG2a, IgE and antigen-provoked 
eosinophils [14]. Consequently, replenishment of 
local cytokine homeostasis (balance in Th1/Th2 
ratio) is an appropriate strategy for discovering 
new anti-asthma drugs. 
 
In this study, tangeretin (4′,5,6,7,8-
pentamethoxyflavone) was tested as an 
intervention for asthma. Studies have revealed 
that tangeritin possesses potential anti-
inflammatory, anti-proliferative and 
chemopreventive properties [15]. In addition, 
previous studies have also showed that 
tangeretin reduced inflammation-related 
cyclooxygenase (COX-2) activity in lung 
epithelial carcinoma cells [15], and provoked G1 
cell cycle arrest in breast and colon carcinomas 
[16]. In view of these beneficial effects of 
tangeretin, its anti-asthma activity was 
investigated in the .present study. The results 
showed that exposure of OVA-treated mice to 
tangeretin inhibited Th2 cytokine secretions (IL-4, 
IL-5 and IL-13) in a dose-dependant fashion, and 
Li & Liu 
Trop J Pharm Res, February 2018; 17(2): 259 
 
increased the secretion of Th1 cytokine 
(interferon-γ) in BALF. Increased production of 
local cytokines (Th1/Th2) is consistent with 
airway hyper-responsiveness, lowered bronchial 
inflammation and cellular infiltration, and 
decreased total IgE, ovalbumin-specific IgE and 
raised IgG2a [17].  The effect exhibited by 
tangeretin could be ascribed to its antioxidant 
and anti-inflammatory properties which have 
been reported in previous studies [15]. 
 
Except for IFN-γ production, all the cytokines 
were affected by tangeretin. This is in agreement 
with previous reports [8]. In this study, the animal 
group sensitized with OVA had lower levels of 
IFN-γ when compared to the saline group and 
drug-treated group. In contrast, a previous study 
reported that the concentration of IFN-γ in the 
blood of sensitized and challenged guinea pigs 
was comparatively higher than that of normal 
controls [18]. This difference in IFN-γ secretion 
could be due to difference in the experimental 
animal models used. There exist a diversity in 
immunization procedure, antigen used, and 
frequency and level of stimulating antigen in the 
various animal models of asthma.  These 
differences could influence asthma-like 
symptoms [18]. Indeed, these conflicting 
observations were also witnessed in the current 
study. Nevertheless, since asthma produces 
diverse manifestations in different models, one 
should take note of the salient, characteristic 
features in a particular animal model such that 
each critical parameter is represented in that 
experimental model. 
 
The animal model employed in this study is 
known to exhibit all the characteristic traits of 
allergic bronchial swelling in human beings. 
However, the model limits one to examination of 
bronchial remodelling, particularly sub-epithelial 
and respiratory airway hypertrophy and 
hyperplasia. Moreover, the OVA used for 
inducing asthma might not be an appropriate 
antigenic agent in humans. Hence, further 
studies are required on the possible ameliorating 
activity of tangeretin using a chronic 




The findings of this study demonstrate the anti-
asthmatic effect of tangeretin against OVA-
provoked respiratory airway allergic asthma in 
mice. The ameliorating effect of tangeretin may 
be mainly due to its effect on cytokine secretion. 
These results suggest that tangeretin may be a 
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